LOS ANGELES--(BUSINESS WIRE)--Cougar Biotechnology, Inc. (NASDAQ:CGRB - News) today announced that positive Phase I data on the Company’s prostate cancer drug candidate CB7630 (abiraterone acetate) was presented as a poster presentation at the ASCO Genitourinary Cancers Symposium that is currently taking place in San Francisco, California.
